<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=US-ASCII">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with donepezil</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with donepezil">
<meta name="Date" content="2003-01-29">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with donepezil</h1>
<!-- received="Wed Jan 29 07:39:00 2003" -->
<!-- isoreceived="20030129143900" -->
<!-- sent="Wed, 29 Jan 2003 09:47:59 -0500" -->
<!-- isosent="20030129144759" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with donepezil" -->
<!-- id="BMEDJIBJGLNDOOANGIDLCEFNCJAA.rms2g@virginia.edu" -->
<!-- charset="US-ASCII" -->
<!-- inreplyto="007601c2c747$a847d300$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20donepezil"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Wed Jan 29 2003 - 07:47:59 MST
</p>
<!-- next="start" -->
<ul>
<li><strong>Next message:</strong> <a href="1612.html">Christian Weisgerber: "POL: Anti-{American,European}ism"</a>
<li><strong>Previous message:</strong> <a href="1610.html">Brett Paatsch: "Debunking Clone claims.  A possible extropian public service."</a>
<li><strong>In reply to:</strong> <a href="1592.html">gts: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1641.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1611">[ date ]</a>
<a href="index.html#1611">[ thread ]</a>
<a href="subject.html#1611">[ subject ]</a>
<a href="author.html#1611">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<em>&gt;
</em><br>
<em>&gt; There is a tremendous amount of favorable research into deprenyl for
</em><br>
<em>&gt; various purposes. It increases lifespan in mice and dogs (and humans,
</em><br>
<em>&gt; hopefully).
</em><br>
<p>### Hopefully?
<br>
<p>----------
<br>
<p>&nbsp;It's also an excellent antidepressant, especially when
<br>
<em>&gt; taken with DL-phenylalanine and B-6 (it increases levels of the
</em><br>
<em>&gt; natural mood enhancer phenylethylamine, and selectively inhibits the
</em><br>
<em>&gt; MAO-B enzyme that breaks down dopamine)
</em><br>
<p>### How does it compare to MAOI's?
<br>
<p>It's not a coincidence that MAOI's are third-line antidepressants - they are
<br>
too risky and not sufficiently effective compared to SSRI's, TCA's, and
<br>
atypicals.
<br>
<p>--------------
<br>
<p><p>. It enhances libido. It is
<br>
<em>&gt; neuroprotective; it almost certainly prevents or delays the onset of
</em><br>
<em>&gt; parkinson's disease in addition to being a treatment for it.
</em><br>
<p>### Quote some studies giving us the &quot;almost certain&quot; feeling.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="1612.html">Christian Weisgerber: "POL: Anti-{American,European}ism"</a>
<li><strong>Previous message:</strong> <a href="1610.html">Brett Paatsch: "Debunking Clone claims.  A possible extropian public service."</a>
<li><strong>In reply to:</strong> <a href="1592.html">gts: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1641.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1611">[ date ]</a>
<a href="index.html#1611">[ thread ]</a>
<a href="subject.html#1611">[ subject ]</a>
<a href="author.html#1611">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sun Feb 02 2003 - 21:26:03 MST
</em></small></p>
</body>
</html>
